<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-7-83</article-id><article-id pub-id-type="pmid">17504528</article-id><article-id pub-id-type="doi">10.1186/1471-2407-7-83</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Frank</surname><given-names>Bernd</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>b.frank@dkfz.de</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Hemminki</surname><given-names>Kari</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>k.hemminki@dkfz.de</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Meindl</surname><given-names>Alfons</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>alfons.meindl@lrz.tu-muenchen.de</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Wappenschmidt</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="I5">5</xref><xref ref-type="aff" rid="I6">6</xref><email>barbara.wappenschmidt@uk-koeln.de</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Sutter</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>Christian.Sutter@med.uni-heidelberg.de</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Kiechle</surname><given-names>Marion</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>marion.kiechle@lrz.tum.de</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Bugert</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>p.bugert@blutspende.de</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Schmutzler</surname><given-names>Rita K</given-names></name><xref ref-type="aff" rid="I5">5</xref><xref ref-type="aff" rid="I6">6</xref><email>rita.schmutzler@uk-koeln.de</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Bartram</surname><given-names>Claus R</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>Cr.Bartram@med.uni-heidelberg.de</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Burwinkel</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>b.burwinkel@dkfz.de</email></contrib></contrib-group><aff id="I1"><label>1</label>Helmholtz-University Group Molecular Epidemiology, German Cancer Research Center, DKFZ, Heidelberg, Germany</aff><aff id="I2"><label>2</label>Division of Molecular Genetic Epidemiology, German Cancer Research Center, DKFZ, Heidelberg, Germany</aff><aff id="I3"><label>3</label>Center for Family Medicine, Karolinska Institute, Huddinge, Sweden</aff><aff id="I4"><label>4</label>Department of Gynaecology and Obstetrics, Klinikum rechts der Isar at the Technical University, Munich, Germany</aff><aff id="I5"><label>5</label>Division of Molecular Gynaeco-Oncology, Department of Gynaecology and Obstetrics, Clinical Center University of Cologne, Germany</aff><aff id="I6"><label>6</label>Center of Molecular Medicine Cologne (CMMC), University Hospital of Cologne, Germany</aff><aff id="I7"><label>7</label>Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany</aff><aff id="I8"><label>8</label>Institute of Transfusion Medicine and Immunology, Red Cross Blood Service of Baden-W&#x000fc;rttemberg-Hessia, University of Heidelberg, Faculty of Clinical Medicine, Mannheim, Germany</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>15</day><month>5</month><year>2007</year></pub-date><volume>7</volume><fpage>83</fpage><lpage>83</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/7/83"/><history><date date-type="received"><day>31</day><month>1</month><year>2007</year></date><date date-type="accepted"><day>15</day><month>5</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 Frank et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Frank et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Frank Bernd b.frank@dkfz.de </dc:author><dc:title> BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>BMC Cancer 7(1): 83-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2407(2007)7:1&#x0003c;83&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2407</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Inactivating and truncating mutations of the nuclear BRCA1-interacting protein 1 (BRIP1) have been shown to be the major cause of Fanconi anaemia and, due to subsequent alterations of BRCA1 function, predispose to breast cancer (BC).</p></sec><sec sec-type="methods"><title>Methods</title><p>We investigated the effect of BRIP1 -64G&#x0003e;A and Pro919Ser on familial BC risk by means of TaqMan allelic discrimination, analysing <italic>BRCA1/BRCA2 </italic>mutation-negative index patients of 571 German BC families and 712 control individuals.</p></sec><sec><title>Results</title><p>No significant differences in genotype frequencies between BC cases and controls for BRIP1 -64G&#x0003e;A and Pro919Ser were observed.</p></sec><sec><title>Conclusion</title><p>We found no effect of the putatively functional BRIP1 variants -64G&#x0003e;A and Pro919Ser on the risk of familial BC.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Germline mutations in the high-penetrance genes <italic>BRCA1 </italic>and <italic>BRCA2 </italic>account for up to 25% of the hereditary forms of breast cancer (BC) [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. The nuclear BRCA1-interacting protein 1 (BRIP1; also referred to as BRCA1-associated C-terminal helicase, BACH1) directly binds the BRCT-motif containing domain of BRCA1, thus likely contributing to its DNA repair and tumour suppressor functions [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. <italic>BRIP1 </italic>deficiency has been described as the causation for cancer-predisposing Fanconi anaemia [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>], and a recent study has identified constitutional truncating <italic>BRIP1 </italic>mutations to confer susceptibility to BC [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>Several genotyping studies have addressed the association between BRIP1 variants and BC risk, but the results have remained controversial [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B11">11</xref>]. The non-conservative BRIP1 Pro919Ser substitition has been previously reported to be associated with an increased BC risk up to age 50 [<xref ref-type="bibr" rid="B12">12</xref>]. We evaluated the effects of BRIP -64G&#x0003e;A, which may affect gene regulation, and Pro919Ser, on a large German familial BC study cohort.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study population</title><p>The familial breast cancer cohort comprised 571 unrelated German, female index cases (19 to 87 years of age; median 45) without deleterious <italic>BRCA1 </italic>and <italic>BRCA2 </italic>mutations. They were collected during the years 1996&#x02013;2005 through the Institute of Human Genetics (Heidelberg, Germany), the Department of Gynaecology and Obstetrics (Cologne, Germany) and the Department of Medical Genetics (Munich, Germany). According to the German Consortium for Hereditary Breast and Ovarian Cancer, breast cancer cases are classified into six categories based on family history: (A1) families with two or more breast cancer cases including at least two cases with onset below the age of 50 years; (A2) families with at least one male breast cancer case; (B) families with at least one breast cancer and one ovarian cancer case; (C) families with at least two breast cancer cases including one case diagnosed before the age of 50 years; (D) families with at least two breast cancer cases diagnosed after the age of 50 years; (E) single cases of breast cancer with age of diagnosis before 35 years [<xref ref-type="bibr" rid="B2">2</xref>]. All women gave written consent to the molecular analysis of the <italic>BRCA1 </italic>and <italic>BRCA2 </italic>genes and potential new breast cancer susceptibility genes. Prior to DNA extraction, their blood (EDTA) was frozen at -20&#x000b0;C. The DNA was isolated by a conventional phenol-chloroform protocol. Mutations in the open reading frame of <italic>BRCA1 </italic>and <italic>BRCA2 </italic>were excluded by applying denaturing high performance liquid chromatography (DHPLC) on all exons, followed by direct sequencing of conspicuous exons. The control series consisted of 712 healthy, unrelated female blood donors (26 to 68 years of age, median 49). They were recruited in 2004 and 2005 by the Institute of Transfusion Medicine and Immunology (Mannheim, Germany) and share the ethnic background with the breast cancer patients. According to the German guidelines for blood donation, all blood donors were examined by a standard questionnaire. Buffy coat samples were taken from the anti-coagulated blood donations and were used for DNA isolation (FlexiGene<sup>&#x000ae; </sup>DNA Kit; Qiagen, Hilden Germany). All blood donors consented to the use of their samples for research studies. The study was approved by the Ethics Committee of the University of Heidelberg (Heidelberg, Germany).</p></sec><sec><title>Genotyping</title><p><italic>BRIP1 </italic>genotyping was done by the TaqMan allelic discrimination method as previously described [<xref ref-type="bibr" rid="B13">13</xref>]. TaqMan primers and probes were provided by the assay-by-design service (Applied Biosystems, Foster City, CA) and designed on the basis of the GenBank <ext-link ext-link-type="gen" xlink:href="NT_010783">NT_010783</ext-link> sequence. Sequences of primers and probes are available upon request.</p></sec><sec><title>Statistical analysis</title><p>Genotype-specific odds ratios (ORs), 95% confidence intervals (95% CIs) and <italic>P </italic>values were computed by unconditional logistic regression using the Statistical Analysis System software (Version 9.1.; SAS Institute Inc., Cary, NC). Haplotypes were inferred using the SNPHAP programme created by D. Clayton [<xref ref-type="bibr" rid="B14">14</xref>]. Power calculation was carried out with the power and sample size calculation software PS version 2.1.31 [<xref ref-type="bibr" rid="B15">15</xref>].</p></sec><sec><title>Transcription factor search</title><p>The search for putative transcription factors was performed using TESS (Transcription Element Search Software, [<xref ref-type="bibr" rid="B16">16</xref>]) and TFSEARCH (Searching Transcription Factor Binding Sites, [<xref ref-type="bibr" rid="B17">17</xref>]).</p></sec></sec><sec><title>Results and discussion</title><p>Mutations in the DNA helicase <italic>BRIP1 </italic>have been implicated in the aetiology of Fanconi anaemia, a genetic disorder that is characterised by congenital abnormalities, progressive bone marrow failure, genomic instability and predisposition to cancer [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. Our study assessed the relevance of the BRIP1 variants -64G&#x0003e;A and Pro919Ser to familial BC. According to transcription factor binding site searches, the replacement of G by A at position -64 leads to the formation of a GATA or CCAAT motif, suggesting an modification of gene expression. BRIP Pro919Ser is located in the BRCA1-interacting domain and may alter protein structure and function.</p><p>Genotype frequencies for the analysed polymorphisms were in agreement with Hardy-Weinberg expectations in controls. No significant differences in genotype frequencies between BC cases and controls for either BRIP1 -64G&#x0003e;A or Pro919Ser were observed (see Table <xref ref-type="table" rid="T1">1</xref>). Adjustment for age made no significant difference to the results, hence only unadjusted ORs are presented. Our findings are in accord with previously published data [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. Though a recent kin-cohort study has shown a strong association with 4.5- to 6.9-fold familial BC risk for Pro919Ser in premenopausal women [<xref ref-type="bibr" rid="B12">12</xref>], our data do not support the observed effect when stratified according to age at diagnosis (see Table <xref ref-type="table" rid="T1">1</xref>). Haplotype analysis with BRIP1 -64G&#x0003e;A and Pro919Ser did not indicate any association with familial BC risk (data not shown).</p><p>The strengths of the present study are represented by a sound sample size and a homogeneous study cohort of a single ethnic group, comprising women selected for familial BC. Only <italic>BRCA1 </italic>and <italic>BRCA2 </italic>mutation-negative familial BC cases were considered in order to avoid effects caused by these high-penetrance susceptibility genes. With the present sample size, we had a power of 80% at a significance level of 0.05 to detect an OR of &#x02265; 1.44 for both -64G&#x0003e;A and Pro919Ser. Moreover, the power of an association study based on cases with a family history of the disease is at least twice higher compared to a study using unselected cases [<xref ref-type="bibr" rid="B18">18</xref>]. As data of well-known risk factors (age of menarche, history of pregnancy etc.) were not available, we ignored to test for gene-environment interaction.</p></sec><sec><title>Conclusion</title><p>Both the BRIP1 -64G&#x0003e;A and Pro919Ser variants show no effect on familial BC risk in the German population.</p></sec><sec><title>Abbreviations</title><p>BC &#x02013; breast cancer</p><p>BACH1 &#x02013; BRCA1-associated C-terminal helicase</p><p>BRIP1 &#x02013; BRCA1-interacting protein 1</p><p>DHPLC &#x02013; denaturing high performance liquid chromatography</p><p>95% C.I. &#x02013; 95% confidence interval</p><p>OR &#x02013; odds ratio</p><p>SNP &#x02013; single nucleotide polymorphism</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>BF conducted the experiments, performed data acquisition and interpretation, and drafted the manuscript. KH participated in the study coordination and revised the manuscript. AM, BW, CS, MK, PB, RKS and CRB collected DNA samples and were responsible for the <italic>BRCA1/BRCA2 </italic>mutation screening. BB designed and coordinated the study and reviewed the manuscript. All authors read and approved the final version of the submitted manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/7/83/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>The German breast cancer samples were collected within a project funded by the Deutsche Krebshilfe. It was supported by the Center of Molecular Medicine Cologne (CMMC), and the EU, LSHC-CT-2004-503465.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Venkitaraman</surname><given-names>AR</given-names></name></person-group><article-title>Cancer susceptibility and the functions of BRCA1 and BRCA2</article-title><source>Cell</source><year>2002</year><volume>108</volume><fpage>171</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">11832208</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(02)00615-3</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meindl</surname><given-names>A</given-names></name><collab>the German Consortium for Hereditary Breast and Ovarian Cancer</collab></person-group><article-title>Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population</article-title><source>Int J Cancer</source><year>2002</year><volume>97</volume><fpage>472</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">11802209</pub-id><pub-id pub-id-type="doi">10.1002/ijc.1626</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cantor</surname><given-names>SB</given-names></name><name><surname>Bell</surname><given-names>DW</given-names></name><name><surname>Ganesan</surname><given-names>S</given-names></name><name><surname>Kass</surname><given-names>EM</given-names></name><name><surname>Drapkin</surname><given-names>R</given-names></name><name><surname>Grossman</surname><given-names>S</given-names></name><name><surname>Wahrer</surname><given-names>DC</given-names></name><name><surname>Sgroi</surname><given-names>DC</given-names></name><name><surname>Lane</surname><given-names>WS</given-names></name><name><surname>Haber</surname><given-names>DA</given-names></name><name><surname>Livingston</surname><given-names>DM</given-names></name></person-group><article-title>BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function</article-title><source>Cell</source><year>2001</year><volume>105</volume><fpage>149</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">11301010</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(01)00304-X</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cantor</surname><given-names>S</given-names></name><name><surname>Drapkin</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Pamidi</surname><given-names>S</given-names></name><name><surname>Livingston</surname><given-names>DM</given-names></name></person-group><article-title>The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations</article-title><source>Proc Natl Acad Sci USA</source><year>2004</year><volume>101</volume><fpage>2357</fpage><lpage>2362</lpage><pub-id pub-id-type="pmid">14983014</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0308717101</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levran</surname><given-names>O</given-names></name><name><surname>Attwooll</surname><given-names>C</given-names></name><name><surname>Henry</surname><given-names>RT</given-names></name><name><surname>Milton</surname><given-names>KL</given-names></name><name><surname>Neveling</surname><given-names>K</given-names></name><name><surname>Rio</surname><given-names>P</given-names></name><name><surname>Batish</surname><given-names>SD</given-names></name><name><surname>Kalb</surname><given-names>R</given-names></name><name><surname>Velleuer</surname><given-names>E</given-names></name><name><surname>Barral</surname><given-names>S</given-names></name><name><surname>Ott</surname><given-names>J</given-names></name><name><surname>Petrini</surname><given-names>J</given-names></name><name><surname>Schindler</surname><given-names>D</given-names></name><name><surname>Hanenberg</surname><given-names>H</given-names></name><name><surname>Auerbach</surname><given-names>AD</given-names></name></person-group><article-title>The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><fpage>931</fpage><lpage>933</lpage><pub-id pub-id-type="pmid">16116424</pub-id><pub-id pub-id-type="doi">10.1038/ng1624</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>CG</given-names></name></person-group><article-title>Fanconi anaemia genes and susceptibility to cancer</article-title><source>Oncogene</source><year>2006</year><volume>25</volume><fpage>5875</fpage><lpage>5884</lpage><pub-id pub-id-type="pmid">16998502</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1209878</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seal</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>D</given-names></name><name><surname>Renwick</surname><given-names>A</given-names></name><name><surname>Elliott</surname><given-names>A</given-names></name><name><surname>Kelly</surname><given-names>P</given-names></name><name><surname>Barfoot</surname><given-names>R</given-names></name><name><surname>Chagtai</surname><given-names>T</given-names></name><name><surname>Jayatilake</surname><given-names>H</given-names></name><name><surname>Ahmed</surname><given-names>M</given-names></name><name><surname>Spanova</surname><given-names>K</given-names></name><name><surname>North</surname><given-names>B</given-names></name><name><surname>McGuffog</surname><given-names>L</given-names></name><name><surname>Evans</surname><given-names>DG</given-names></name><name><surname>Eccles</surname><given-names>D</given-names></name><collab>Breast Cancer Susceptibility Collaboration (UK)</collab><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Rahman</surname><given-names>N</given-names></name></person-group><article-title>Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles</article-title><source>Nat Genet</source><year>2006</year><volume>38</volume><fpage>1239</fpage><lpage>1241</lpage><pub-id pub-id-type="pmid">17033622</pub-id><pub-id pub-id-type="doi">10.1038/ng1902</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vahteristo</surname><given-names>P</given-names></name><name><surname>Yliannala</surname><given-names>K</given-names></name><name><surname>Tamminen</surname><given-names>A</given-names></name><name><surname>Eerola</surname><given-names>H</given-names></name><name><surname>Blomqvist</surname><given-names>C</given-names></name><name><surname>Nevanlinna</surname><given-names>H</given-names></name></person-group><article-title>BACH1 Ser919Pro variant and breast cancer risk</article-title><source>BMC Cancer</source><year>2006</year><volume>6</volume><fpage>19</fpage><pub-id pub-id-type="pmid">16430786</pub-id><pub-id pub-id-type="doi">10.1186/1471-2407-6-19</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>AG</given-names></name><name><surname>Flanagan</surname><given-names>J</given-names></name><name><surname>Marsh</surname><given-names>A</given-names></name><name><surname>Pupo</surname><given-names>GM</given-names></name><name><surname>Mann</surname><given-names>G</given-names></name><name><surname>Spurdle</surname><given-names>AB</given-names></name><name><surname>Lindeman</surname><given-names>GJ</given-names></name><name><surname>Visvader</surname><given-names>JE</given-names></name><name><surname>Brown</surname><given-names>MA</given-names></name><name><surname>Chenevix-Trench</surname><given-names>G</given-names></name><collab>Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer</collab></person-group><article-title>Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer</article-title><source>Breast Cancer Res</source><year>2005</year><volume>7</volume><fpage>R1005</fpage><lpage>1016</lpage><pub-id pub-id-type="pmid">16280053</pub-id><pub-id pub-id-type="doi">10.1186/bcr1336</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karppinen</surname><given-names>SM</given-names></name><name><surname>Vuosku</surname><given-names>J</given-names></name><name><surname>Heikkinen</surname><given-names>K</given-names></name><name><surname>Allinen</surname><given-names>M</given-names></name><name><surname>Winqvist</surname><given-names>R</given-names></name></person-group><article-title>No evidence of involvement of germline BACH1 mutations in Finnish breast and ovarian cancer families</article-title><source>Eur J Cancer</source><year>2003</year><volume>39</volume><fpage>366</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">12565990</pub-id><pub-id pub-id-type="doi">10.1016/S0959-8049(02)00498-7</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rutter</surname><given-names>JL</given-names></name><name><surname>Smith</surname><given-names>AM</given-names></name><name><surname>Davila</surname><given-names>MR</given-names></name><name><surname>Sigurdson</surname><given-names>AJ</given-names></name><name><surname>Giusti</surname><given-names>RM</given-names></name><name><surname>Pineda</surname><given-names>MA</given-names></name><name><surname>Doody</surname><given-names>MM</given-names></name><name><surname>Tucker</surname><given-names>MA</given-names></name><name><surname>Greene</surname><given-names>MH</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Struewing</surname><given-names>JP</given-names></name></person-group><article-title>Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals</article-title><source>Hum Mutat</source><year>2003</year><volume>22</volume><fpage>121</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">12872252</pub-id><pub-id pub-id-type="doi">10.1002/humu.10238</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sigurdson</surname><given-names>AJ</given-names></name><name><surname>Hauptmann</surname><given-names>M</given-names></name><name><surname>Chatterjee</surname><given-names>N</given-names></name><name><surname>Alexander</surname><given-names>BH</given-names></name><name><surname>Doody</surname><given-names>MM</given-names></name><name><surname>Rutter</surname><given-names>JL</given-names></name><name><surname>Struewing</surname><given-names>JP</given-names></name></person-group><article-title>Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes</article-title><source>BMC Cancer</source><year>2004</year><volume>4</volume><fpage>9</fpage><pub-id pub-id-type="pmid">15113441</pub-id><pub-id pub-id-type="doi">10.1186/1471-2407-4-9</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>B</given-names></name><name><surname>Hemminki</surname><given-names>K</given-names></name><name><surname>Wirtenberger</surname><given-names>M</given-names></name><name><surname>Bermejo</surname><given-names>JL</given-names></name><name><surname>Bugert</surname><given-names>P</given-names></name><name><surname>Klaes</surname><given-names>R</given-names></name><name><surname>Schmutzler</surname><given-names>RK</given-names></name><name><surname>Wappenschmidt</surname><given-names>B</given-names></name><name><surname>Bartram</surname><given-names>CR</given-names></name><name><surname>Burwinkel</surname><given-names>B</given-names></name></person-group><article-title>The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk</article-title><source>Carcinogenesis</source><year>2005</year><volume>26</volume><fpage>643</fpage><lpage>647</lpage><pub-id pub-id-type="pmid">15550452</pub-id><pub-id pub-id-type="doi">10.1093/carcin/bgh342</pub-id></citation></ref><ref id="B14"><citation citation-type="other"><article-title>David Clayton</article-title><ext-link ext-link-type="uri" xlink:href="http://www-gene.cimr.cam.ac.uk/clayton/"/></citation></ref><ref id="B15"><citation citation-type="other"><article-title>PowerSampleSize</article-title><ext-link ext-link-type="uri" xlink:href="http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize"/></citation></ref><ref id="B16"><citation citation-type="other"><article-title>TESS : Transcription Element Search System</article-title><ext-link ext-link-type="uri" xlink:href="http://www.cbil.upenn.edu/tess"/></citation></ref><ref id="B17"><citation citation-type="other"><article-title>TFSEARCH</article-title><ext-link ext-link-type="uri" xlink:href="http://www.cbrc.jp/research/db/TFSEARCH.html"/></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Antoniou</surname><given-names>AC</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name></person-group><article-title>Polygenic inheritance of breast cancer: Implications for design of association studies</article-title><source>Genet Epidemiol</source><year>2003</year><volume>25</volume><fpage>190</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">14557987</pub-id><pub-id pub-id-type="doi">10.1002/gepi.10261</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Genotype distributions of the BRIP1 variants -64G&#x0003e;A (rs2048718<sup>&#x000a7;</sup>) and Pro919Ser (rs4986764<sup>&#x000a7;</sup>) among unrelated German <italic>BRCA1/2 </italic>mutation-negative familial breast cancer patients and healthy, unrelated female control subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>BRIP -64G&#x0003e;A</bold></td><td align="center" colspan="2"><bold>CASES</bold></td><td align="center" colspan="2"><bold>CONTROLS</bold></td><td></td><td></td><td></td></tr><tr><td></td><td align="center"><bold>n</bold></td><td align="center"><bold>%</bold></td><td align="center"><bold>n</bold></td><td align="center"><bold>%</bold></td><td align="center"><bold>OR*</bold></td><td align="center"><bold>95% CI</bold></td><td align="center"><bold><italic>P</italic></bold></td></tr></thead><tbody><tr><td align="center"><bold>All </bold>&#x003a3;</td><td align="center"><bold>571</bold></td><td></td><td align="center"><bold>712</bold></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="center">GG</td><td align="center">181</td><td align="center">31.7</td><td align="center">228</td><td align="center">32.0</td><td align="center">1</td><td></td><td></td></tr><tr><td align="center">GA</td><td align="center">283</td><td align="center">49.6</td><td align="center">340</td><td align="center">47.8</td><td align="center">1.05</td><td align="center">0.82&#x02013;1.35</td><td align="center">0.71</td></tr><tr><td align="center">AA</td><td align="center">107</td><td align="center">18.7</td><td align="center">144</td><td align="center">20.2</td><td align="center">0.94</td><td align="center">0.68&#x02013;1.29</td><td align="center">0.68</td></tr><tr><td align="center">GA+AA</td><td align="center">390</td><td align="center">68.3</td><td align="center">484</td><td align="center">68.0</td><td align="center">1.02</td><td align="center">0.80&#x02013;1.29</td><td align="center">0.90</td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="center"><bold>&#x0003c; 50 years </bold>&#x003a3;</td><td align="center"><bold>406</bold></td><td></td><td align="center"><bold>367</bold></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="center">GG</td><td align="center">132</td><td align="center">32.5</td><td align="center">113</td><td align="center">30.8</td><td align="center">1</td><td></td><td></td></tr><tr><td align="center">GA</td><td align="center">190</td><td align="center">46.8</td><td align="center">180</td><td align="center">49.0</td><td align="center">0.90</td><td align="center">0.65&#x02013;1.25</td><td align="center">0.54</td></tr><tr><td align="center">AA</td><td align="center">84</td><td align="center">20.7</td><td align="center">74</td><td align="center">20.2</td><td align="center">0.97</td><td align="center">0.65&#x02013;1.45</td><td align="center">0.89</td></tr><tr><td align="center">GA+AA</td><td align="center">274</td><td align="center">67.5</td><td align="center">254</td><td align="center">69.2</td><td align="center">0.92</td><td align="center">0.68&#x02013;1.25</td><td align="center">0.61</td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="center"><bold>50 years </bold>&#x003a3;</td><td align="center"><bold>165</bold></td><td></td><td align="center"><bold>345</bold></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="center">GG</td><td align="center">49</td><td align="center">29.7</td><td align="center">115</td><td align="center">33.3</td><td align="center">1</td><td></td><td></td></tr><tr><td align="center">GA</td><td align="center">93</td><td align="center">56.4</td><td align="center">160</td><td align="center">46.4</td><td align="center">1.36</td><td align="center">0.90&#x02013;2.08</td><td align="center">0.15</td></tr><tr><td align="center">AA</td><td align="center">23</td><td align="center">13.9</td><td align="center">70</td><td align="center">20.3</td><td align="center">0.77</td><td align="center">0.43&#x02013;1.37</td><td align="center">0.38</td></tr><tr><td align="center">GA+AA</td><td align="center">116</td><td align="center">70.3</td><td align="center">230</td><td align="center">66.7</td><td align="center">1.18</td><td align="center">0.79&#x02013;1.77</td><td align="center">0.41</td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="center"><bold>BRIP Pro919Ser</bold></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="center"><bold>All </bold>&#x003a3;</td><td align="center"><bold>571</bold></td><td></td><td align="center"><bold>712</bold></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="center">Pro/Pro</td><td align="center">181</td><td align="center">31.7</td><td align="center">226</td><td align="center">31.7</td><td align="center">1</td><td></td><td></td></tr><tr><td align="center">Pro/Ser</td><td align="center">295</td><td align="center">51.7</td><td align="center">365</td><td align="center">51.3</td><td align="center">1.01</td><td align="center">0.79&#x02013;1.29</td><td align="center">0.94</td></tr><tr><td align="center">Ser/Ser</td><td align="center">95</td><td align="center">16.6</td><td align="center">121</td><td align="center">17.0</td><td align="center">0.98</td><td align="center">0.70&#x02013;1.37</td><td align="center">0.91</td></tr><tr><td align="center">Pro/Ser+Ser/Ser</td><td align="center">390</td><td align="center">68.3</td><td align="center">486</td><td align="center">68.3</td><td align="center">1.00</td><td align="center">0.79&#x02013;1.27</td><td align="center">0.97</td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="center"><bold>&#x0003c; 50 years </bold>&#x003a3;</td><td align="center"><bold>406</bold></td><td></td><td align="center"><bold>367</bold></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="center">Pro/Pro</td><td align="center">121</td><td align="center">29.8</td><td align="center">118</td><td align="center">32.2</td><td align="center">1</td><td></td><td></td></tr><tr><td align="center">Pro/Ser</td><td align="center">219</td><td align="center">53.9</td><td align="center">182</td><td align="center">49.6</td><td align="center">1.17</td><td align="center">0.85&#x02013;1.62</td><td align="center">0.33</td></tr><tr><td align="center">Ser/Ser</td><td align="center">66</td><td align="center">16.3</td><td align="center">67</td><td align="center">18.3</td><td align="center">0.96</td><td align="center">0.63&#x02013;1.47</td><td align="center">0.85</td></tr><tr><td align="center">Pro/Ser+Ser/Ser</td><td align="center">285</td><td align="center">70.2</td><td align="center">249</td><td align="center">67.8</td><td align="center">1.12</td><td align="center">0.82&#x02013;1.51</td><td align="center">0.48</td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="center"><bold>50 years </bold>&#x003a3;</td><td align="center"><bold>165</bold></td><td></td><td align="center"><bold>345</bold></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="center">Pro/Pro</td><td align="center">60</td><td align="center">36.4</td><td align="center">108</td><td align="center">31.3</td><td align="center">1</td><td></td><td></td></tr><tr><td align="center">Pro/Ser</td><td align="center">76</td><td align="center">46.1</td><td align="center">183</td><td align="center">53.0</td><td align="center">0.75</td><td align="center">0.49&#x02013;1.13</td><td align="center">0.17</td></tr><tr><td align="center">Ser/Ser</td><td align="center">29</td><td align="center">17.6</td><td align="center">54</td><td align="center">15.7</td><td align="center">0.97</td><td align="center">0.56&#x02013;1.68</td><td align="center">0.90</td></tr><tr><td align="center">Pro/Ser+Ser/Ser</td><td align="center">105</td><td align="center">63.6</td><td align="center">237</td><td align="center">68.7</td><td align="center">0.80</td><td align="center">0.54&#x02013;1.18</td><td align="center">0.26</td></tr></tbody></table><table-wrap-foot><p>*As compared to GG and Pro/Pro homozygotes, respectively; &#x000a7; dbSNP rs#; Hardy-Weinberg equilibrium test was undertaken using Pearson's goodness-of-fit chi-square test with one degree of freedom. Adjustment for age did not change the ORs, assuming that the distribution of the BRIP1 genotypes is age-independent.</p></table-wrap-foot></table-wrap></sec></back></article> 